多重向的烯酸合物作为抗炎症和高脂血症的强有力的药物
Panagiotis Theodosis-Nobelos1, Eleni A Rekka2
1Department of Pharmacy, School of Health Sciences, Frederick University, 1036 Nicosia, Cyprus.
Molecules (Basel, Switzerland)
|June 13, 2025
概括
新型酸衍生物显示出显著的抗炎和降脂作用,性能优于一些现有的药物. 这些多目标化合物对治疗涉及炎症和异常脂质水平的退行性疾病有前途.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 瓦尔酸衍生物正在探索多目标治疗潜力.
- 开发新的抗炎和降脂剂对于管理退行性疾病至关重要.
研究的目的:
- 合成与生物活性部分结合的新型烯酸衍生物.
- 评估这些新化合物的抗炎,抗氧化和降脂活性.
主要方法:
- 瓦尔酸衍生物与 thiomorpholine,4-aminopyridine,血清甲基,trolox 和肉酸部分的合成.
- 在实验室中评估大豆氧化酶抑制,激素清除和脂质过氧化.
- 在体内评估抗炎作用和降脂效果在超脂性大鼠.
主要成果:
- 合成的化合物表现出显著的急性抗炎活性,往往超过非类固醇抗炎药物的活性.
- 化合物显示大豆脂氧化酶抑制,激素清除和脂质过氧化减弱.
- 测试的化合物有效降低了血脂标记物; 化合物2显著降低了总胆固醇,甘油三和LDL胆固醇,与simvastatin相比,但降低了较高的甘油三.
结论:
- 新型酸衍生物具有多功能性质,包括强大的抗炎和脂质调节作用.
- 这些化合物与trolox相比,显示出更高的抗氧化能力.
- 合成的药物代表了开发用于与炎症和脂质失调相关的退行性疾病的多功能治疗方法的有希望的候选人.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
588
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
588
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
271
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
271
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160


